| Cell line name |
DU145-R |
|---|
| Accession |
CVCL_C0QR |
|---|
| Resource Identification Initiative |
To cite this cell line use: DU145-R (RRID:CVCL_C0QR) |
|---|
| Comments |
Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI_45863; Paclitaxel (Taxol).
Derived from site: Metastatic; Brain; UBERON=UBERON_0000955. |
|---|
| Sequence variations |
- Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:9884; RB1; Simple; p.Lys715Ter (c.2143A>T); ClinVar=VCV001786615; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line).
|
|---|
| Disease |
Prostate carcinoma (NCIt: C4863) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_0105 (DU145) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
69Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=30244336; DOI=10.1007/s00345-018-2501-6
Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F.
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
World J. Urol. 37:1117-1126(2019) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_C0QR
|
|---|
| Encyclopedic resources |
Wikidata; Q112929465
|
|---|
| Entry history |
|---|
| Entry creation | 23-Jun-2022 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 6 |
|---|
